Phase 2, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Inclusion Criteria:

•Diagnosis of non-small cell lung cancer
•Metastatic or locally advanced disease
•Prior platinum chemotherapy or immunotherapy
•Test result showing genetic change in MET tumor gene
•At least one tumor that can be measured on a radiographic scan

Exclusion Criteria:

•Prior treatment with inhibitor of MET or HGF
•Prior positive test for EGFR mutation or ALK gene rearrangement
•Uncontrolled tumor in the brain
Phase II
Raul Mena, M.D.
Anneliese Cadena
  • Disney Family Cancer Center (DFCC)
  • Providence Los Angeles Research Center